stockrow
Friday 6 November 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
102.20
6.18
+6.44%
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) EBITDA
Oruka Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$127.0M, compared with −$90.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$158.0M. Over the past ten years it has ranged from −$127.0M (fiscal 2025) to −$5.7M (fiscal 2019) — the current reading is the lowest in ten years. Oruka Therapeutics, Inc. ranks 480th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$127.0M | — |
| FY2024 | −$90.3M | — |
| FY2023 | −$7.2M | — |
| FY2022 | −$10.5M | — |
| FY2021 | −$19.2M | — |
| FY2020 | −$9.7M | — |
| FY2019 | −$5.7M | — |
| FY2018 | −$8.1M | — |
| FY2017 | −$18.2M | — |
| FY2016 | −$16.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$51.0M | — |
| Mar 2026 | −$36.8M | — |
| Dec 2025 | −$35.1M | — |
| Sep 2025 | −$35.1M | — |
| 42 more quarters | Free account |
Against its own ten years
Low −$127.0M
High −$5.7M
Ten-year median
−$11.2M
Current reading's percentile
9
EBITDA against peers
| Company | EBITDA |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| AXSM Axsome Therapeutics, Inc. compare | −$139.8M |
| ORKA Oruka Therapeutics, Inc. | −$158.0M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item